NCT03305445View on ClinicalTrials.gov

Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL

PHASE1CompletedINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

May 14, 2018

Primary Completion Date

April 1, 2021

Study Completion Date

April 1, 2021

Conditions

Relapsed Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma

Interventions

DRUG

Ipilimumab

Ipilimumab (1mg/kg)

DRUG

Nivolumab

Nivolumab (3mg/kg)

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Icahn School of Medicine at Mount Sinai

OTHER

NCT03305445 - Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL | Biotech Hunter | Biotech Hunter